GLP-1s for Alzheimer’s: Novo Nordisk announces trial conclusion

Data from the Evoke trials suggests that GLP-1 drugs that treat type 2 diabetes do not have a significant effect on Alzheimer’s disease, Novo Nordisk has confirmed.

About The Author

Jeffrey L. Klump

I am 62 years old and widowed with 2 children. I live in Creve Coeur, MO. USA which is a suburb of Saint Louis. I am a Digital Marketer, Blogger, Writer, SEO Expert, and Work from Home Business Opportunity Specialist. I am the owner & administrator of the MEK Enterprises Blog. Please contact me if you have any questions. Thank you.

See author's posts